Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.56%
#2 Luxxcoin Luxxcoin +46.85%
#3 Layer3 Layer3 +32.82%
#4 ResearchCoin ResearchCoin +31.78%
#5 Reactive Network Reactive Network +24.01%
#6 Orderly Network Orderly Network +17.27%
#7 Bitgert Bitgert +17.01%
#8 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +10.20%
#9 Useless Coin Useless Coin +10.11%
#10 OpenVPP OpenVPP +9.68%
Coin of the day
Resolv wstUSR Resolv wstUSR
Settings
Language
ENGLISH
Currency
USD
Theme
CSL Limited CSL Limited

CSL Limited

CSL
Rank in Stocks #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Share Price
$99.32
Market Cap
$48.20B
Change (1 day)
0.98%
Change (1 year)
-32.14%
Country
AU
Trade CSL Limited (CSL)

Category

Healthcare
Earnings for CSL Limited (CSL)
Earnings in Dec 2025 TTM: $1.61B
According to CSL Limited latest financial reports the company's current earnings are $1.61B. In 2024 the company made an earning of $3.38B, an increase over its 2023 earnings that were of $2.66B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for CSL Limited from 2000 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B 1,170.24%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B 187.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 224.03%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B 32.42%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -10.11%
NL